US health care giant Johnson & Johnson’s (NYSE: JNJ) European subsidiary Janssen-Cilag GmbH yesterday announced it has completed the acquisition of CorImmun GmbH, a privately held drug development company in Germany, for an undisclosed upfront payment and a contingent future clinical milestone payment.
CorImmun's lead compound, COR-1, is a small cyclic peptide currently in early clinical development for the treatment of heart failure. COR-1 has been shown in preclinical studies to improve heart function by decreasing autoimmune, beta 1 receptor-simulating antibody effects. Under terms of the agreement, Janssen and its affiliates immediately assume full development and global commercialization responsibilities for the compound.
Heart failure is generally a progressive disease characterized by the heart muscle's inability to adequately pump oxygenated blood through the body. An estimated 23 million people around the globe have been diagnosed with heart failure, a number that is projected to increase. For most causes of heart failure, there is no known cure.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze